Integrating Behavioral Science and AI-Powered Emotional Analysis into HCP Positioning Research for a Novel Bispecific Oncology Therapy

A pharmaceutical company was developing positioning for a novel bispecific therapy with a first-in-class mechanism across multiple solid tumor types. The scientific story was complex — tumor microenvironment modulation, dual-target biology, combination potential — and had to resonate with oncologists in academic and community settings across the US, Europe, and Japan. Standard concept testing could identify which positioning territory HCPs preferred; the client needed to know why certain messages resonated, why others triggered skepticism, and what cognitive patterns drove those reactions.

Blue Matter conducted a multi-phase global qualitative positioning study and layered in two proprietary behavioral science capabilities. A structured cognitive bias analysis evaluated HCP responses against a framework of 13 heuristics and biases — including confirmation bias, anchoring, ambiguity aversion, optimism bias, and status quo bias — separating rational objections from reflexive, heuristic-driven reactions. The team then deployed EmotiCore™, Blue Matter’s AI-powered emotional sentiment tool, which combines transcript analysis, vocal tone detection, facial expression recognition, and contextual cues to surface implicit as well as stated responses, flagging latent frustration, implicit trust, and hidden skepticism that standard qualitative coding would miss.

Three findings changed the client’s strategy. Skepticism toward the boldest territory came from confirmation bias and anchoring rather than the data itself, as HCPs filtered the product’s clinical signals through entrenched beliefs about immunotherapy efficacy in certain tumor settings; knowing the objection was heuristic, the client redesigned messaging to disrupt those anchors instead of piling on more data. EmotiCore showed that the most mechanistically grounded territory generated the strongest implicit trust even when verbal reactions were lukewarm, while abstract tumor-microenvironment claims triggered hidden frustration masked by neutral responses — clarifying which narrative frame to lead with and which to retire. And optimism bias among a subset of early adopters flagged a ready-made audience for peer-to-peer advocacy. The client moved from picking a preferred concept to building a positioning architecture calibrated to how oncologists actually process information, with language edits, sequencing recommendations, and segment-level activation plans tied to the behavioral evidence.